Alivus Life Sciences · NSE: ALIVUS · BSE: 543322
Q2 FY22 results · Jul–Sep 2021
Alivus Life Sciences reported revenue from operations of ₹561.76 crore and net profit of ₹115.20 crore for Q2 FY22 (Jul–Sep 2021), on a standalone basis.
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 561.76 | — | — | 524.90 | +7.0% |
| Other income | 2.09 | — | — | 3.99 | −47.6% |
| Total income | 563.85 | — | — | 528.88 | +6.6% |
| Profit before tax | 152.53 | — | — | 134.97 | +13.0% |
| Net profit for the period | 115.20 | — | — | 100.91 | +14.2% |
| EPS, basic (₹) | 9.83 | — | — | 9.36 | not comparable |
| Net margin (%) | 20.5 | — | 19.2 |
Standalone
- Filed with BSE
- 11 Nov 2021, 16:41 IST
- Board meeting
- 10 Nov 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE